Maxim Group analyst Jason McCarthy maintained a Buy rating on Mesoblast yesterday. The company’s shares opened today at $19.33.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
According to TipRanks, McCarthy is an analyst with an average return of -14.1% and a 37.22% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as OS Therapies Incorporated, Atossa Therapeutics, and SCYNEXIS.
Currently, the analyst consensus on Mesoblast is a Strong Buy with an average price target of $24.00.
The company has a one-year high of $22.00 and a one-year low of $7.09. Currently, Mesoblast has an average volume of 260.6K.
Read More on MESO:
Disclaimer & DisclosureReport an Issue
- Mesoblast reports Q2 Ryoncil revenue up 66% y/y
- Mesoblast receives J-Code for Ryoncil from Medicare & Medicaid Services
- Mesoblast’s U.S. Origin Designation Shields Products from Tariffs
- Largest borrow rate increases among liquid names
- Buy Rating for Mesoblast Driven by Strong Ryoncil Launch and Strategic Financial Moves
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
/Broadcom%20Inc%20logo%20on%20building-by%20Poetra_%20RH%20via%20Shutterstock.jpg)
/AI%20(artificial%20intelligence)/Data%20Center%20by%20Caureem%20via%20Shutterstock%20(2).jpg)
/Nvidia%20logo%20on%20phone%20screen%20with%20stock%20chart%20by%20xalien%20via%20Shutterstock.jpg)